Tuesday, November 15, 2022

Fw: Ref.: (LML) Novel approaches in the treatment of Hansen’s disease in the US

 

Leprosy Mailing List – November 15,  2022

 

Ref.:  (LML) Novel approaches in the treatment of Hansen's disease in the US

 

From:  Barbara Stryjewska, Baton Rouge, USA

 

 

Dear Pieter,


I would like to share with the LML readers , the latest publication regarding RMM treatment  as a pre-print.


Novel approaches in the treatment of Hansen's disease (Leprosy): a case series
of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the

United States. Carlos Franco-Paredes,  Elizabeth Garcia-Creighton, Andrés Henao-Martinez, et al. Ther Adv Infect Dis 2022, Vol. 9: 1–10 DOI: 10.1177/ 20499361221135885


Abstract: The World Health Organization (WHO) recommends multidrug therapy (MDT) for the treatment of paucibacillary and multibacillary forms of leprosy, also known as Hansen's disease (HD). MDT combinations of dapsone, rifampin, and clofazimine have reduced the prevalence of the disease but are not without adverse effects impacting regimen adherence. Hence, an urgent need exists to consider alternative MDT regimens with an improved safety profile that promotes treatment adherence. Herein, we described a case series of 10 patients with HD (nine patients with multibacillary leprosy and one with pure neural leprosy) treated with monthly rifampin, moxifloxacin, and minocycline (RMM). Etc., etc.

 

Sincerely,

 

Barbara M. Stryjewska, M. D.

Chief Medical Officer

Principal Investigator

Clofazimine IND # 67,033

National Hansen's Disease Program

HSB/HRSA/HHS

9181 Interline Ave

Baton Rouge, LA  70809

Ph #: (225) 756-3700

Fax # (225) 756-3706

NHDP Web Site:  http://www.hrsa.gov/hansens-disease/


 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/c4cf97b2-ad3d-4ecb-a550-58cd49a41d07n%40googlegroups.com.

No comments: